Description: Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Home Page: www.amarincorp.com
Iconic Offices, The Greenway
Dublin,
112-114
Ireland
Phone:
353 0 166 99020
Officers
| Name | Title |
|---|---|
| Mr. Aaron D. Berg | CEO, President & Director |
| Dr. Steven B. Ketchum Ph.D. | Executive VP, President of Research & Development and Chief Scientific Officer |
| Mr. Jonathan N. Provoost | Executive VP, Chief Legal & Compliance Officer and Secretary |
| Mr. Peter Fishman | VP, Global Controller, Principal Financial Officer & Principal Accounting Officer |
| Mr. Jordan Zwick | Senior VP of Corporate Business Development & Investor Relations |
| Mr. Laurent Abuaf | President of Europe & Senior VP |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs |
| Dr. David Keenan Ph.D. | Executive VP of Technical Operations & President of Europe |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 588.2353 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3458 |
| Price-to-Sales TTM: | 0.7973 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 275 |